ACAD Downgraded by UBS -- Price Target Lowered to $23.00
UBS downgraded Acadia Pharmaceuticals (ACAD) from Buy to Neutral, lowering its price target from $49.00 to $23.00. The company's stock is currently trading at $18.62, with a GF Value™ of $25.90, suggesting it is 28.1% undervalued. Insider sales totaled $1,019,973 over the past three months, and the company has a GF Score™ of 79/100.
How this was made
The 30-second read
Why it matters
UBS's rating cut reduces the stock's upside narrative and may prompt short sellers.
Market read
A fresh downgrade of a small‑cap biotech can move the stock sharply and affect sector sentiment.
What to watch
Insider sales could reflect portfolio rebalancing rather than loss of confidence; the GF valuation suggests upside.
Background
Acadia Pharmaceuticals focuses on CNS disorders with products like NUPLAZID and DAYBUE. The firm has a market cap of ~ $3.2B.
Ticker impact
UBS downgraded Acadia Pharmaceuticals from Buy to Neutral and cut the price target to $23, a fresh analyst rating change.
likely downward pressure as investors price in the lower target
Analyst rating cuts historically lead to short-term price declines, especially with a 53% target reduction.
Market effects
Biopharma sector may see heightened scrutiny on CNS drug pipelines.
U.S. biotech stocks could face broader sell‑offs.
Limited to investors tracking small‑cap biotech equities.
Counterpoint
The downgrade may be overly pessimistic given the company's undervalued GF score and pipeline potential.
Key entities
- companyAcadia Pharmaceuticals
Biopharma developing CNS therapies.
- analystUBS
Equity research firm issuing the downgrade.
